blog | Scribe Therapeutics

Skip to content

Login

Login

Subscribe to our Newsletter

Go Back to Home

Go Back to Blog

IPOs, 2026, Scribe Therapeutics

Scribe Therapeutics (SCTX) Targets $100 Million IPO to Advance Next-Generation CRISPR Medicines for Cardiovascular Disease

Eric Friedman

Jul 20, 2026 12:37:27 PM

Scribe Therapeutics (NASDAQ: SCTX) has filed for an initial public offering of 7.15 million shares p...

Subscribe to our Newsletter

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025